Загрузка...
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
BACKGROUND: The efficacy and safety of OnabotulinumtoxinA (BOTOX®) in adults with chronic migraine (CM) were demonstrated in the PREEMPT program. However, the dosage used in this study was flexible from 155 U to 195 U at the physician’s discretion. Therefore, the objective of this prospective study...
Сохранить в:
| Опубликовано в: : | J Headache Pain |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Milan
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4720620/ https://ncbi.nlm.nih.gov/pubmed/26792662 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10194-016-0591-3 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|